

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 June 2008 (12.06.2008)

PCT

(10) International Publication Number
WO 2008/070692 A2

(51) International Patent Classification: **Not classified**

(21) International Application Number:
PCT/US2007/086434

(22) International Filing Date:
5 December 2007 (05.12.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/868,789 6 December 2006 (06.12.2006) US

(71) Applicant (for all designated States except US):
SMITHKINE BEECHAM CORPORATION [US/US];
One Franklin Plaza, PO Box 7929, Philadelphia, PA
19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FANG, Jing** [CN/US]; GlaxoSmithKline, c/o Corporate Intellectual Property Department, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **TANG, Jun** [CN/US]; GlaxoSmithKline, c/o Corporate Intellectual Property Department, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **CARPENTER, Andrew J** [US/US]; GlaxoSmithKline, c/o Corporate Intellectual Property Department, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **PECKHAM, Gregory** [US/US]; GlaxoSmithKline, c/o Corporate Intellectual Property Department, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **CONLEE, Christopher R** [US/US]; GlaxoSmithKline, c/o Corporate Intellectual Property Department, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). **DU, Kien S** [US/US]; GlaxoSmithKline, c/o Corporate Intellectual Property Department, Five Moore Drive, PO Box 13398, Research Triangle Park, NC

27709 (US). **KATAMREDDY, Subba Reddy** [IN/US]; GlaxoSmithKline, c/o Corporate Intellectual Property Department, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(74) Agent: **DEPPENBROCK, Bonnie, L.**; GlaxoSmithKline, c/o Corporate Intellectual Property Department, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- without international search report and to be republished upon receipt of that report

(54) Title: CHEMICAL COMPOUNDS AND USES

(57) Abstract: The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.



WO 2008/070692 A2